Surrozen Gets FDA Clearance for SZN-8141 Trial, Triggering $95.1M in Funding

Key Facts

1Surrozen announced that its IND application for SZN-8141 for the treatment of diabetic macular edema has become effective.

2The milestone triggers the second closing of a March 2025 private placement, expected to provide approximately $95.1M in gross proceeds.

Surrozen announced that its Investigational New Drug (IND) application for SZN-8141, a treatment for diabetic macular edema, has become effective following FDA clearance. According to a GlobeNewswire report, this milestone allows the company to advance the program into clinical development, with the first patient dosing expected in the fourth quarter of 2026.

The regulatory clearance triggers the second closing of a private placement originally established in March 2025, which is expected to provide approximately $95.1 million in gross proceeds. Regarding market performance, SRZN closed at $30 on October 1, 2026, after trading between a low of $29.72 and a high of $32 during that session.